BoYen Therapeutics, Inc.

NT$23.45As of Sun 8 Nov 2026, 12:00 UTC

TPEx:7891—

Country Taiwan

PE (Fwd) •••

TSR 10Y CAGR —

Div yield —

ROE —

—

Beta (5Y) —

PE TTM —

TSR TTM —

Mkt cap —

ROIC —

SE Grade™

Value

Quality

Moat

Consensus

Reference

NT$23

(2.01%)

24.93%

Sell 0|10|3|7|9

TTM

FYE 31 Dec TWD

FY2016

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

10Y

Peers

5.125

RevenueNT$B

2.353

2.460

2.611

2.733

2.933

3.203

3.382

3.568

3.768

4.068

5.661

6.76%

6.33%

5.89

Revenue growth%

18.30

20.88

19.16

20.74

18.47

16.46

16.26

17.85

16.22

16.39

27.80

16.39

18.07

10.75

Gross margin%

22.24

23.85

23.54

25.85

28.76

31.16

30.30

29.45

26.72

28.66

13.35

29.45

27.69

28.80

Operating margin%

17.12

16.17

13.57

11.52

9.28

8.45

10.07

9.00

11.89

9.54

7.47

9.54

10.80

7.08

Net margin%

11.44

11.21

14.06

11.80

10.06

12.57

13.17

11.96

10.75

13.45

8.76

12.57

11.88

15.32

P/E ratio (avg)x

10.83

10.62

11.76

12.32

12.98

13.07

12.88

13.63

14.01

16.52

35.27

13.63

12.93

33.62

EV/EBITx

8.795

8.002

7.045

7.016

6.174

5.379

5.013

5.269

5.599

5.568

32.72

5.379

5.887

26.66

FCF yield (avg)%

6.71

5.36

4.05

5.92

4.18

5.17

5.96

6.70

7.29

5.28

23.29

5.96

5.64

9.64

FCF margin%

19.26

20.33

19.95

22.35

19.46

22.34

21.24

21.04

19.44

20.54

26.62

21.04

20.44

0.745

FCF / Net incomex

1.606

1.735

1.895

2.082

1.950

1.727

1.888

1.973

1.796

1.880

0.877

1.880

1.884

3.54

ROIC%

6.54

8.48

10.89

12.18

13.66

15.84

15.62

18.27

17.63

20.36

8.95

17.63

14.64

10.17

Return on equity%

11.48

11.37

13.10

15.73

16.92

15.31

17.08

17.62

20.38

23.03

7.58

17.62

16.32

25.96

Return on assets%

7.18

7.24

10.14

10.06

8.86

6.48

6.93

9.68

10.42

10.59

9.17

9.68

9.27

1.06

EPSNT$

0.63

0.68

0.76

0.81

0.91

0.92

1.00

0.98

0.96

0.97

1.17

1.43%

5.28%

—

15.15

EPS growth%

22.47

23.61

26.19

28.44

29.64

30.14

27.33

29.82

31.35

31.57

7.36

30.14

29.04

0.79

Bookvalue per shNT$

1.86

1.83

2.14

2.33

2.45

2.68

2.93

3.36

3.80

4.02

0.52

10.43%

9.50%

—

2.13

FCF per shareNT$

0.99

1.04

1.08

1.01

0.94

0.96

0.89

0.83

0.88

0.84

0.95

(2.31%)

(1.19%)

—

0.91

Dividend per shNT$

1.65

1.70

1.72

1.57

1.66

1.56

1.51

1.68

1.69

1.85

0.61

2.16%

2.44%

—

5.16

Div yield (avg)%

8.15

6.21

3.36

5.04

6.94

6.84

7.53

7.60

5.90

4.75

4.08

6.84

6.53

21.38

Payout ratio%

8.40

10.37

10.25

9.97

12.55

15.22

12.88

15.26

13.05

11.30

11.69

13.05

11.93

274.6

Shares (diluted)M

328.5

343.4

375.9

426.2

420.1

442.8

437.9

487.3

486.6

468.2

286.0

2.19%

5.07%

11.99

Buyback yield%

8.22

5.26

3.02

1.91

4.27

1.86

0.40

28.83

0.40

1.89

0.829

D/E ratiox

1.322

1.410

1.361

1.401

1.255

1.197

1.070

1.119

0.975

0.984

1.547

1.070

1.226

2.047

Enterprise valueNT$B

1.097

1.116

1.156

1.283

1.467

1.384

1.500

1.480

1.619

1.855

3.079

4.80%

6.17%

2.573

LT debtNT$B

0.275

0.289

0.277

0.271

0.283

0.259

0.252

0.253

0.288

0.271

2.419

(0.86%)

(0.68%)

Peers (US$13.26M)

Cap (US$)

Anbogen Therapeutics…

46.46M

—

Anya Biopharm Inc.

38.85M

—

TSA International Co.…

38.54M

—

Makers Laboratories…

13.46M

16.92x

Capital

TTM

10Y

Leveragex

6.991

0.212

0.240

EBIT/Intx

1.089

1.211

1.106

Own earn%

(3.74)

(51.60)

(22.16)

Sh yield%

17.16

7.93

7.96

Owners

Insiders/Inst%

13.18

66.72

Short interest%

1.21

SBC / revenue%

5.50

Record

10Y

Profitable years

10/10

Revenue growth years

10/10

EPS growth years

10/10

Dividend streakyrs

Op margin range%

8–17

$1 testx

—

Incr. ROIC%

BoYen Therapeutics, Inc., through its own proprietary prodrug technology platform, engages in drug research and discovery. The company's products include BY-101, used for treating acute myeloid leukemia (AML), and BY-102 and BY-103, for the treatment of multiple sclerosis and acute hematologic malignancies. The company was founded in 2010 and is headquartered in Taipei, Taiwan.

Growth vs revenue

Latest

Trend

10Y CAGR

Rel growth

Revenue

NT$4.068B

6.33%

1.00×

Cost of revenue

NT$2.278B

6.22%

0.99×

Operating expenses

NT$511.8M

6.11%

0.98×